Novartis AG planted another stake in the fertile digital therapeutics terrain through a collaboration with Pear Therapeutics Inc. The Basel, Switzerland-based pharma will work with Pear, of Boston, to advance development of Pear's Thrive digital therapeutic for individuals with schizophrenia.